Acute Glycogen Synthase Kinase-3 Inhibition Modulates Human Cardiac Conduction

Glycogen synthase kinase 3 (GSK-3) inhibition has emerged as a potential therapeutic target for several diseases, including cancer. However, the role for GSK-3 regulation of human cardiac electrophysiology remains ill-defined. We demonstrate that SB216763, a GSK-3 inhibitor, can acutely reduce condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Gang, Brumback, Brittany D., Huang, Lei, Zhang, David M., Yin, Tiankai, Lipovsky, Catherine E., Hicks, Stephanie C., Jimenez, Jesus, Boyle, Patrick M., Rentschler, Stacey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research - Preclinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626903/
https://www.ncbi.nlm.nih.gov/pubmed/36337924
http://dx.doi.org/10.1016/j.jacbts.2022.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626903/
https://www.ncbi.nlm.nih.gov/pubmed/36337924
http://dx.doi.org/10.1016/j.jacbts.2022.04.007

Ejemplares similares